Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD)

Dr. Deepa S. Mandlik is an Associate Professor of Pharmacology with more than 18 years of experience in teaching, research, and academic administration. She is currently serving in the Department of Pharmacology at the Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune, Maharashtra, India. Dr. Mandlik completed her Bachelor of Pharmacy (B. Pharm.) from the University of Pune, where she secured First Rank in the university. She subsequently obtained her Master of Pharmacy (M. Pharm.) in Pharmacology from the University of Pune and earned her Ph.D. in Pharmaceutical Sciences. An accomplished academician and researcher, Dr. Mandlik has published more than 88 research papers in reputed national and international peer-reviewed journals. Her research has received widespread recognition, with an h-index of 20 and more than 1,850 citations. She has authored more than seven pharmaceutical books and contributed over twenty book chapters published by internationally renowned publishers.Dr. Mandlik is a recognized postgraduate and Ph.D. research supervisor. She has successfully guided several postgraduate and doctoral research scholars and has received research grants from various funding agencies in support of her scientific work. Her research interests encompass preclinical evaluation of herbal medicines, inflammation and immunology, cancer, diabetes, osteoporosis, rheumatoid arthritis and inflammatory bowel disease. Her work focuses on the development and pharmacological evaluation of novel therapeutic strategies and the translation of scientific discoveries into clinically relevant healthcare solutions. In addition to her research contributions, Dr. Mandlik has actively participated in curriculum development, academic administration, and professional training, contributing significantly to pharmaceutical education and research in India. Dr. Satish K. Mandlik is currently serving as an Associate Professor in the Department of Pharmaceutics at Bharati Vidyapeeth (Deemed to be University)'s Poona College of Pharmacy, Pune, Maharashtra, India. With over 18 years of teaching and research experience, he has made significant contributions to pharmaceutical education, research, and academic development. Dr. Mandlik completed his Bachelor of Pharmacy (B. Pharm.) from the University of Pune, securing Fourth Rank in the university. He obtained his Master of Pharmacy (M. Pharm.) in Quality Assurance from Goa University, where he was awarded First Rank for his outstanding academic performance.An accomplished researcher and academician, Dr. Mandlik has published more than 50 research papers in reputed national and international peer-reviewed journals. His scholarly contributions have earned him an h-index of 17 with more than 1,450 citations, reflecting the quality and impact of his research. He has also authored more than Six Pharmaceutical books and contributed Eight international book chapters published by renowned publishers.Dr. Mandlik is a recognized PG and Ph.D. Guide and his commitment to research has been recognized through research grants exceeding ₹8 lakhs received from various funding agencies.His major research interests include nanotechnology-based drug delivery systems, targeted drug delivery, Quality by Design (QbD), Design of Experiments (DoE), pharmaceutical optimization techniques, formulation development, and pharmaceutical quality assurance. He has actively contributed to research in advanced drug delivery systems and pharmaceutical product development, with a focus on translating scientific innovations into practical healthcare solutions.

• Part 1 Immunity in inflammatory bowel diseases1 Overview of inflammatory bowel diseases: from bench to bedside2 Pathophysiology of inflammatory bowel disease: innate immune system3 Understanding the intestinal epithelial barrier in IBD4 Role of innate and adaptive immunity in IBD5 Role of dendritic cells in pathogenesis of IBD6 Potential role of natural killer cells in pathogenesis of inflammatory bowel disease7 Immunobiology of T-Cells and B-Cells in inflammatory bowel disease8 Immunobiology of intestinal epithelial cells in inflammatory bowel disease9 Immunobiology of monocytes, macrophages, and polymorphonuclear Cells (PMN) in inflammatory bowel disease10 Cytokine networks in the pathophysiology of inflammatory bowel disease11 Role of chemokines in the pathophysiology of inflammatory bowel disease12 Transforming growth factor (TGF)-β, activins and follistatin: A key regulator in inflammatory bowel disease 14 Role of Occludin, Claudin-2, and Zonulin in inflammatory bowel diseasePart B Immunotherapy in inflammatory bowel diseases15 Basics of immunotherapy in inflammatory bowel disease16 Targeting tumor necrosis factor (TNF)-alpha in inflammatory bowel disease17 Integrin inhibition in inflammatory bowel disease18 Janus kinase (JAK) inhibitors in inflammatory bowel disease19 Stem cell and cell-based therapies in inflammatory bowel disease20 Interleukin inhibition: targeting cytokine pathways21 Key molecular targets for antisense therapy in inflammatory bowel disease22 Therapeutic approaches targeting sphingolipids in inflammatory bowel disease23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets24 Immune checkpoint modulation as a therapeutic strategy in inflammatory bowel disease25 Potential targets for chimeric antigen receptor (CAR)-T cells in inflammatory bowel disease26 Personalized medicine in inflammatory bowel disease immunotherapy27 Advances in immunotherapy and emerging agents28 Immunotherapy resistance and management of failure in inflammatory bowel disease29 Safety, long-term outcomes, and side effects of immunotherapy30 Immunotherapy and the gut microbiome in inflammatory bowel disease

Select Guide Rating